Jun 15, 2020
Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
Jun 13, 2020
EHA25Virtual: Study of Subcutaneous Daratumumab Shows Improved Clinical Outcomes in the Treatment of Patients with Amyloidosis
Jun 08, 2020
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
Jun 01, 2020
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
May 29, 2020
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 28, 2020
GNS Healthcare and Collaborators Identify PHF19 as Marker of Aggressive Multiple Myeloma
May 28, 2020
Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic
May 22, 2020
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
May 14, 2020
Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting
May 13, 2020
Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 13, 2020
Amgen Showcases Oncology Pipeline At ASCO 2020
May 13, 2020
Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting
May 05, 2020
KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer
May 05, 2020
Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
May 01, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO(TM) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
Apr 30, 2020
Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 27, 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Apr 26, 2020
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 03, 2020
Case Study: Treating COVID-19 in a Patient with Multiple Myeloma
Mar 27, 2020
HealthTree.org to Launch Observational Study Evaluating the Impact of COVID-19 on Multiple Myeloma Patients